ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2023
Changes in the national prevalence of asthma and coronavirus disease 2019 fatality: A population-based cross-sectional study.
Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adult-onset asthma induced by COVID-19: A case report.Heliyon · 2024Article
- National Trends and Prevalence of Atopic Dermatitis and Pandemic-Related Factors among Korean Adults, 2007-2021.International archives of allergy and immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) mitigation and containment strategies implemented by each country can influence the prevalence of asthma and its fatality.
objectiveTo analyze the trend of asthma prevalence and COVID-19 fatality in children and adults with asthma.
methodsThe prevalence of asthma and fatalities were compared among the peaks of 5 pandemic waves in Mexico.
resultsAmong patients with COVID-19, the prevalence rates of asthma among children were as follows: wave I, 3.5%; wave II, 2.6%; wave III, 2.2%; wave IV, 2.4%; and wave V, 1.9% (P for trend < .001); the prevalence rates of asthma among adults were as follows: wave I, 2.5%; wave II, 1.8%; wave III, 1.5%; wave IV, 1.7%; and wave V, 1.6% (P for trend < .001). The rates of fatality because of COVID-19 among individuals with asthma were as follows: wave I, 8.9%; wave II, 7.7%; wave III, 5.0%; wave IV, 0.9%; and wave V, 0.2% (P for trend < .001).
conclusionThe prevalence rates of asthma and fatalities from COVID-19 suggest a gradual reduction throughout the pandemic in Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.